EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden

Yue Huang, Qin Yu, Elaine Tan Su Yin, Guoqing Wei, Wenjun Wu, Alex H. Chang, He Huang, Yongxian Hu

ImmunoMedicine · 2022

DOI: 10.1002/imed.1032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoMedicine, 2022. Verfasst von Yue Huang und 7 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The genetically engineered chimeric antigen receptor T cell (CAR‐T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR‐T cell products in patients with high tumor burden and prior tumor‐reductive treatment. Here we reported a relapsed/refractory acute lymphoblastic leukemia patient with high leukemia burden and central nervous system (CNS) involvement. The patient responded to donor‐derived HLA‐matched allogeneic CAR‐T treatment, with the achievement of quick complete remission. And for the first time, we revealed the development of a cerebral CRS in situ after allogeneic CAR‐T therapy.

Zitieren

APA

Huang, Y., Yu, Q., Yin, E. T. S., Wei, G., Wu, W., Chang, A. H., Huang, H., & Hu, Y. (2022). HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden. ImmunoMedicine. https://doi.org/10.1002/imed.1032

Vancouver

Huang Y, Yu Q, Yin ETS, Wei G, Wu W, Chang AH, et al. HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden. ImmunoMedicine. 2022. doi:10.1002/imed.1032

BibTeX
@article{Huang2022,
  author = {Huang, Yue and Yu, Qin and Yin, Elaine Tan Su and Wei, Guoqing and Wu, Wenjun and Chang, Alex H. and Huang, He and Hu, Yongxian},
  title = {HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden},
  journal = {ImmunoMedicine},
  year = {2022},
  doi = {10.1002/imed.1032}
}
Kostenlos starten →